Benzinga | Sep 22, 2021 06:19AM EDT

Goldman Sachs Downgrades Axcella Health to Neutral, Lowers Price Target to $5

Goldman Sachs analyst Paul Choi downgrades Axcella Health (NASDAQ:AXLA) from Buy to Neutral and lowers the price target from $9 to $5.